Starpharma Holdings Limited (SPHRY)

Market Cap	218.54M +700.5%
Revenue (ttm)	9.72M +250.6%
Net Income	-2.16M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147
Open	5.50
Previous Close	5.30
Day's Range	5.40 - 5.71
52-Week Range	0.67 - 5.71
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhance...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 40
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPHRY

Financial Performance

In fiscal year 2025, Starpharma Holdings's revenue was 5.85 million, a decrease of -40.04% compared to the previous year's 9.76 million. Losses were -9.99 million, 22.4% more than in 2024.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error